A first-in-class investigational antitubercular agent has shown early bactericidal activity with a low, once-daily oral dose after 14 days of treatment. The Phase IIa study evaluated GSK’s GSK3036656 in participants with drug-susceptible pulmonary tuberculosis. The company hopes GSK3036656 could be a component of simpler treatment regimens in the future which could help address the TB […]
